Novo Nordisk's 'There's Only One Ozempic' Campaign Reunites Stars

Novo Nordisk Launches Innovative Ozempic Campaign

Novo Nordisk announced a new consumer campaign for Ozempic (semaglutide) injection 0.5 mg, 1 mg, and 2 mg. Titled "There's Only One Ozempic," it reimagines traditional pharmaceutical advertising. The campaign features actors Justin Long and John Hodgman, known for their mid-2000s TV commercials.

Through levity, lively banter, and relatable everyday moments, the duo promotes informed discussions about GLP-1 treatment options. It targets adults with type 2 diabetes, highlighting Ozempic's FDA-approved uses amid a crowded market of GLP-1s and unapproved compounded "semaglutide."

Campaign Goals and Unique Approach

The campaign meets people where they are, using educational messages and humor to cut through the noise. It aims to foster meaningful conversations between consumers and healthcare professionals. By focusing on patient education, it spotlights what sets the iconic Ozempic brand apart.

"Not all GLP-1s are the same, and people with type 2 diabetes should talk with their doctors about whether Ozempic is right for them," said Ed Cinca, Senior Vice President, Marketing & Patient Solutions at Novo Nordisk Inc. "With our campaign, we're cutting through the noise with straightforward education about how Ozempic fits into care."

Ozempic's FDA-Approved Indications

Ozempic is the only FDA-approved GLP-1 that improves blood sugar along with diet and exercise and reduces the risk of major cardiovascular events and worsening kidney disease. This provides key information for choosing a type 2 diabetes treatment.

• Improves blood sugar (glucose) in adults with type 2 diabetes, along with diet and exercise.
• Reduces risk of major cardiovascular events (heart attack, stroke, or death) in adults with type 2 diabetes and known heart disease.
• Reduces risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.

Ozempic has the most FDA-approved uses among GLP-1s for type 2 diabetes. It is not approved for use in children.

Distinguishing Ozempic from Compounded Semaglutide

In a landscape filled with unapproved compounded "semaglutide," clarity is crucial. Only Novo Nordisk manufactures FDA-approved semaglutide medicines like Ozempic. Products without the Ozempic label are not FDA-approved, lacking rigorous review for safety, effectiveness, and quality.

The campaign uses relatable storytelling and familiar voices to help information stand out. It encourages seeking credible details and discussing FDA-approved options with doctors.

Actors' Perspectives on the Campaign

"Humor has a way of opening the door to conversations people might otherwise avoid," said Justin Long. "This campaign uses that idea thoughtfully and meets people where they are consuming content while helping them feel comfortable enough to learn more about their health."

John Hodgman added, "It's important for people to learn more about their medication options and have that discussion with their doctors. What I appreciate about this campaign is the way it encourages meaningful conversations that can truly make a difference."

Justin Long and John Hodgman are paid spokespeople for Novo Nordisk and do not live with type 2 diabetes or take Ozempic.

Important Safety Information for Ozempic

Do not share your Ozempic pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.

What is the Most Important Information About Ozempic?

Ozempic may cause serious side effects, including possible thyroid tumors, including cancer. Tell your health care provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Ozempic and medicines that work like Ozempic caused thyroid tumors, including thyroid cancer. It is not known if Ozempic will cause thyroid tumors or medullary thyroid carcinoma (MTC) in people.

• Do not use Ozempic if you or any of your family have ever had MTC or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Do not use Ozempic if you are allergic to semaglutide or any ingredients in Ozempic.

Before Using Ozempic

Tell your health care provider if you have:

• Problems with your pancreas or history of diabetic retinopathy.
• Severe stomach problems like gastroparesis.
• Upcoming surgery or procedures with anesthesia.
• Pregnancy plans or breastfeeding (stop Ozempic at least 2 months before planning pregnancy).

Inform your provider about all medicines, including insulin or sulfonylureas.

Possible Side Effects of Ozempic

Serious side effects may include:

• Pancreatitis: Severe abdominal pain that may radiate to your back, with or without vomiting.
• Changes in vision.
• Hypoglycemia: Especially with sulfonylureas or insulin. Symptoms: dizziness, blurred vision, anxiety, sweating, hunger, shakiness, fast heartbeat.
• Dehydration and kidney problems: From nausea, vomiting, diarrhea. Drink fluids to prevent.
• Severe stomach problems.
• Serious allergic reactions: Swelling, breathing issues, rash, rapid heartbeat.
• Gallbladder problems: Upper abdominal pain, fever, jaundice.
• Aspiration during surgery: Inform providers you take Ozempic.

Common side effects: nausea, vomiting, diarrhea, abdominal pain, constipation.

What is Ozempic?

Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:

• Along with diet and exercise to improve blood sugar in adults with type 2 diabetes.
• To reduce major cardiovascular event risk in adults with type 2 diabetes and heart disease.
• To reduce worsening kidney disease risk in adults with type 2 diabetes and chronic kidney disease.

It is not known if Ozempic is safe and effective for children.